| http://www.w3.org/ns/prov#value | - Three deaths resulted from causes other than treatment or disease.DISCUSSIONTop of pageAbstractPATIENTS AND METHODSRESULTSDISCUSSIONCONFLICT OF INTEREST DISCLOSURESREFERENCESThe benefit for treating locally advanced, nonmetastatic pancreatic cancer remains limited, with median survival ranging from 8 to 10 months.43 In the current study of 78 patients, a combination of gemcitabine and 5FU with rad
|
